| Cetuximab in place of cisplatin |
NCT01663259 (3) |
7th edition stage III-IV disease (excluding N3 or T4), smoking history <10 pack years |
Cetuximab given in place of cisplatin during concurrent CRT |
Recurrence rate at 3 years |
| Immunotherapy in place of cisplatin |
NCT03799445 (4) |
8th edition stage 1 and 2 (T1 N2, T2 N1-N2, T3 N0-N2) excluding T1N0-N1 and T2N0 |
Single arm study of IMRT with nivolumab and ipilimumab in place of cisplatin |
Dose limiting toxicity, complete response rate at 6 months, progression free survival at 2 years |
| Radiation therapy dose reduction and/or omission of adjuvant chemotherapy |
NCT03323463 (5) |
AJCC 8th edition T1-2/N1-2b |
Patients receive reduced dose RT (30 Gy) over 2 weeks during concurrent CRT |
Treatment effectiveness at 2 years |
|
NCT02254278 (NRG HN002 trial) (6) |
AJCC 7th edition T1-T2, N1-N2b or T3, N0-N2b |
Patients randomized to receive 60 Gy RT with or without weekly cisplatin |
Dysphagia severity, 2-year progression free survival |
|
NCT03952585 (7) |
AJCC 8th edition T1-2, N1, M0 or T3, N0-N1, M0 |
Patients randomized to receive standard CRT, reduced dose RT with cisplatin, or reduced dose RT with nivolumab |
2-year progression free survival and quality of life (MDADI) |
| Induction chemotherapy followed by reduced radiation or chemoradiation |
NCT04012502 (8) |
AJCC 8th edition T1-2/N1-3 (except T1N1M0 and single LN <3 cm) or T3-4N0-3M0 in China |
Patients with good response to induction chemotherapy undergo reduced dose adjuvant RT (60 Gy) and omit concurrent cisplatin |
2-year progression free and overall survival |
| Surgery followed by reduced adjuvant therapy |
NCT02215265 (PATHOS Trial) (9) |
AJCC TNM 7th edition stage T1-T3, N0-N2b |
Transoral laser resection of tumors followed by reduced dose adjuvant RT |
Overall survival, MD Anderson Dysphagia Inventory (MDADI) score at 2 years |
|
NCT02908477 (DART-HPV Trial) (10) |
Patients who have undergone transoral resection and have T3/T4 primary disease, ENE, LVI, PNI, or N2b disease or below |
Transoral resection followed by standard CRT or reduced dose RT with concurrent chemotherapy |
Treatment toxicity, overall survival, quality of life |
|
NCT01898494 (ECOG 3311 Trial) (11) |
AJCC 7th T1-T2 OPSCC and N1-N2b neck disease |
Transoral resection of tumor and neck dissection followed by risk-adjusted adjuvant treatment |
2-year progression free survival |
|
NCT03729518 (12) |
AJCC 7th pathologic T0-3 and N0-N2b disease with <5 positive lymph nodes |
Reduced dose (50 Gy) RT with sparing of primary tumor bed in appropriate patients |
2-year locoregional control |
|
NCT01687413 (ADEPT Trial) (13) |
Patients that have undergone transoral resection and neck dissection with negative margins at primary site, ECS in nodal metastasis must be present |
Reduced dose adjuvant RT and removal of chemotherapy |
5-year disease free survival and locoregional control |
|
NCT03396718 (DELPHI Trial) (14) |
Patients who underwent surgical resection HPV+ OPSCC |
Intermediate risk patients will be treated with reduced dose RT to tumor and neck |
2-year locoregional recurrence |
